<unk>  is approved by U.S. Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in individuals of age 12 and up. It may also be prescribed off-label by physicians to treat anxiety disorders and panic disorder as well as neuropathic pain (including fibromyalgia). For anxiety and neuropathic pain,<unk>  is used primarily to augment other treatments.<unk>  may be used alongside selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or benzodiazepines for anxiety, or antidepressants, gabapentin, other anticonvulsants, or opioids for neuropathic pain. It is effective as monotherapy and combination therapy with other antiepileptic drugs in the treatment of partial seizure. The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended against the use of<unk>  in the treatment of insomnia due to poor effectiveness and very low quality of evidence.
Tiagabine
Retigabine
Pivagabine
Mesuximide
Ethosuximide
Brivaracetam
Lamotrigine
Levetiracetam